- The FDA ordered a complex pharmacy to stop creating a less expensive version of popular weight loss drugs such as Ozempic and Zepbound.
- This command comes after federal officials determine that there is no longer GLP-1 drug shortage.
- People who rely on multi -drugs say that the brand version is too expensive, so you may need to stop taking the drug.
The ban on the weight loss drug of the so -called copycat version containing the active ingredient trijafide was effective on March 19.
Similar prohibitions on copycat weight loss drugs containing active ingredients semaglu tides will be effective on April 22.
The FDA announced the updated guidelines after the federal judge. I ruled About the Outsourcing Facility Association (OFA)
similar suit It is considered on behalf of a pharmacy that produces a cheap version of Semaglutide.
Complex drugs are not approved by the FDA, so the organs do not check safety, effects or quality. But it can be sold in certain situations.
However, in December 2024, FDA officials presentation The lack of drugs is over. They still ordered a transition period to combine pharmacies to stop the manufacturing of drugs protected by patents and provided exclusive rights to ELI Lilly and Novo Nordisk.
Those who take this inexpensive drug are concerned about losing products that help you lose weight. They now say that they should now pay much more money for brand drug treatment, or decide to stop taking GLP-1 drugs and to restore lost weight.
Experts say the FDA decision can make people reject important medical tools.
“The reason for the high demand is that the drug is the most effective drug for weight loss.” I AliA general surgeon, obesity surgeon, and Memorialcare weight loss center in the Orange Coast Medical Center in the MD and California Fountain Valley.
The big problem is whether Ellie Lily and Novo Nordis can produce sufficient GLP-1 drugs to meet demand if they manufacture pharmacies in a combination of pharmacies.
There is also a question of whether the prices of Ozempic, Zepbound, Wegovy and Mounjaro will rise without competition for copy cats.
The officials of ELI Lilly and Novo Nordisk did not respond to the request of Healthline about this article.
The company that sells complex weight loss drugs has sweared to continue to help customers.
The statement provided to the RO official’s healthline said, “We will continue to try to help patients access the best treatment for individual needs and goals.
“GLP-1 is helping millions of Americans to improve their health. A continuous approach to safe, inexpensive and consistently available treatment options is important when fighting against obesity.
He and her officials are a New report The lack of GLP-1 drugs still states that it is still in the United States.
Nevertheless, ALI expects that ELI Lilly and Novo Nordisk will be able to fully manufacture weight loss drugs to meet demand.
ALI said that the price of the brand name GLP-1 drug is not expected to increase significantly due to the pressure to make the company’s drug relatively cheaper.
But he does not mean that people can afford, even if they are enough to supply and the price does not rise.
ALI told Healthline, “Even if the drug can be used, health insurance companies do not deal with this drug for many people.
He also added that consumers are concerned that they can buy cheap weight loss drugs in markets other than the United States.
“People may not get what they pay,” Ali said.
He pointed out that some people are eligible to undergo stomach detours as an alternative to weight loss without using drugs.
Bailey Fields, a 27 -year -old resident of Minnesota, has polycystic ovary syndrome (PCOS), and most of all, he can cause weight gain and potential 2 diabetes.
Fields cost HealthLine costs $ 199 compared to $ 675 per month in Mounjaro for previous semaglutide medication.
She has a PCOS and is at risk of diabetes, so Fields’s doctor prescribes Mounjaro. Nevertheless, Fields mentioned that health insurance companies will only include weight loss medication costs to develop type 2 diabetes.
Fields tries to maintain weight, but if you can’t buy COP Cat Semaglutide products anymore, you’re worried that you can’t do it.
“I don’t know what’s going to happen if I stop it,” she said.
The field is not alone. 45 -year -old Tennessee resident Todd Kennedy relies on a composite semagluide to maintain weight and hopes to lose more weight. He is concerned that the ban on complex details can be dangerous.
Kennedy now pays $ 165 a month for HIMS & HERS products. He told him that the brand name version of the same drug would cost $ 1,500 a month. He could not afford more expensive versions to Healthline and called the FDA decision as “myopia.”
Kennedy said, “It provides people with tools.” I think it doesn’t help anyone to remove valuable and effective tools. “
Ozempic and Mounjaro have been approved for FDA for treatment of type 2 diabetes. However, Ozempic is often out of the label for weight loss.
These products work by aiming at the brain or affecting certain hormones, suppressing appetite and making people feel less hungry.
Those who prescribed the drug are usually wearing specific diets and exercise routines.
Ali said that these drugs are effective because they focus on the source of weight loss problems.
“By treating the source, they are more likely to succeed,” he said.
ALI pointed out that drugs are part of a new strategy in the medical field to treat people with weight management problems.
“As a chronic disease, seeing obesity has a slow change and a slow change that it should be treated in that way,” he said.
